Innovative Diagnostic Tools Eysz’s focus on developing AI-based software that analyzes passive eye movements offers a new approach for neurodiagnostics, providing an opportunity to partner with clinics and hospitals seeking advanced, non-invasive diagnostic solutions for neurological disorders.

Growing Market Potential With a mission to impact over one billion people living with neurological conditions such as epilepsy and ADHD, Eysz is positioned to expand into large, underserved markets, making it an attractive target for organizations focused on innovative neurological healthcare products.

Customization and Personalization Eysz’s ability to help clinicians create personalized care plans through detailed seizure and neurocognitive data presents an opportunity to collaborate with healthcare providers and medical device companies aiming to enhance patient-specific treatments.

Funding and Revenue Growth Although still in the early revenue stage with under $10 million earnings and $1 million in funding, the company's technological advancements suggest significant growth potential, making it a worthwhile prospect for investors and strategic partners in healthtech.

Technology Enablement Utilizing cloud platforms such as Amazon Web Services and integrating advanced analytics tools, Eysz’s tech infrastructure indicates readiness for scalable software deployment, providing an avenue for technology partners to enhance or expand AI and data analysis capabilities.